Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2025-07-04 Regulatory Filings
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2025
Regulatory Filings Classification · 87% confidence The document is a Hong Kong Stock Exchange (HKEX) Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” summarizing movements in issued shares, treasury shares, share options and repurchases for the month ended 30 June 2025. This is a standard regulatory return under the Exchange’s Listing Rules rather than a standalone financial report, earnings release, management discussion, or specific event announcement. It does not fit any more specific category (e.g., share issue (SHA) or transaction in own shares (POS) cover only one transaction type, and other categories like dividends, M&A, or board changes are irrelevant). Therefore it falls under the fallback category Regulatory Filings (RNS).
2025-07-04 English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF ENZESHU IN CHINA BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings Classification · 95% confidence The document is a brief voluntary corporate announcement on the Hong Kong Stock Exchange regarding the approval for marketing of a new drug (ENZESHU®). It does not present financial results, corporate governance changes, dividends, M&A activity, or a full report; instead it is a general business development notice. This type of announcement falls under the general regulatory filings or miscellaneous category (RNS).
2025-07-03 English
DISCLOSEABLE TRANSACTION - AMENDMENT TO THE LICENSE AGREEMENT WITH IDORSIA
Regulatory Filings Classification · 90% confidence The document is an announcement under the Hong Kong Listing Rules regarding a disclosable transaction (amendment to a license agreement). It sets out terms of the transaction and Listing Rules implications. It is not a full financial report (10-K/IR), not an earnings release (ER), not a proxy or dividend notice, nor a regulatory stress test. It is a standard regulatory announcement of a corporate transaction without involving share issuance or M&A. Therefore, it falls under the general Regulatory Filings category (RNS) as the fallback for miscellaneous regulatory announcements.
2025-06-23 English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF QUVIVIQ IN CHINA BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings Classification · 75% confidence The document is a voluntary corporate announcement by Simcere Pharmaceutical Group Limited regarding the marketing approval of a new drug in China. It is not a financial report, earnings release, management presentation, regulatory proxy, dividend notice, share transaction, or any other specialized category. Therefore it falls into the fallback “Regulatory Filings” category for miscellaneous announcements (Code: RNS).
2025-06-20 English
VOLUNTARY ANNOUNCEMENT - ENTERING INTO LICENSE AGREEMENT WITH NEXTCURE IN RELATION TO ADCs
Regulatory Filings Classification · 76% confidence The document is a voluntary corporate announcement published on the Hong Kong Exchange about entering into a license agreement with NextCure. It does not present financial results (ER/IR/10-K), board or management changes (MANG), share issuances (SHA), or any other specific category. It is not a presentation or transcript, nor a governance or AGM document. As it does not fit any specialized category, it falls into the general regulatory announcements fallback (RNS).
2025-06-16 English
(UPDATED) FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2024
Notice of Dividend Amount Classification · 95% confidence The document is a formal cash dividend announcement by Simcere Pharmaceutical Group Limited detailing the final dividend for the year ended December 31, 2024, including dividend amount, record date, ex-dividend date, payment date, and related information. This matches the definition of a Notice of Dividend Amount (Code: DIV).
2025-06-13 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.